Loading
Life sciences · Journal article
Frontiers in Medicine · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Serum procalcitonin (PCT) is conventionally used as a biomarker for bacterial infection, however, emerging evidence suggests that PCT may also be elevated in patients with lung cancer in the absence of infection. We report a patient with stage IVB pulmonary large cell neuroendocrine carcinoma (LCNEC) who experienced tumor recurrence after achieving partial response(PR) with multimodal therapy. During remission, serum PCT remained relatively stable at a baseline level of 1.62 ng/mL (normal range: 0–0.05 ng/mL). Subsequently, PCT increased markedly to 61.57 ng/mL despite the absence of definitive radiographic progression and rose further to 93.14 ng/mL when tumor recurrence was ultimately confirmed. Notably, marked elevation in PCT preceded radiographic confirmation of recurrence by more than one month, with no clinical or microbiological evidence of concurrent infection. This biochemical lead time suggests that serial PCT monitoring may have potential value as an adjunctive biomarker for the early detection of recurrence in advanced LCNEC, although further studies are required to establish its clinical utility.